Welcome
Support Centre
19 March 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) in patients with a new or recurrent episode of depression
ISRCTN ISRCTN63565713
ClinicalTrials.gov identifier
Public title A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) in patients with a new or recurrent episode of depression
Scientific title
Acronym N/A
Serial number at source LA01.01.0008A
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Depression
Participants - inclusion criteria 1. Written informed consent
2. Diagnosis of major depressive disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth edition [DSM-IV])
3. Score of between and including 16 and 25 on the Hamilton Depression Rating Scale (HDRS)
4. No treatment with any antidepressant medication (including St John's Wort) in the last 12 weeks from the date of Visit 0 (screen)
5. Male or female of any race aged 18-75
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/2003
Anticipated end date 01/01/2004
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Four groups randomly allocated to placebo, 0.5 g, 1 g or 2 g/day ethyl EPA on a double blind basis.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Laxdale Ltd (UK)
Trial website
Publications
Contact name Dr  Harald  Murck
  Address Laxdale Ltd
Kings Park House
Laurelhill Business Park
Polmaise Road
  City/town Stirling
  Zip/Postcode FK7 9JQ
  Country United Kingdom
  Tel +44 (0)1786 476001
  Fax +44 (0)1786 473137
  Email hmurck@laxdale.co.uk
Sponsor Laxdale Ltd (UK)
  Address Kings Park House
Laurelhill Business Park
Polmaise Road
  City/town Stirling
  Zip/Postcode FK7 9JQ
  Country United Kingdom
  Tel +44 (0)1786 476001
  Fax +44 (0)1786 473137
  Email admin@Laxdale.co.uk
  Sponsor website: http://www.laxdale.co.uk
Date applied 03/02/2003
Last edited 19/05/2008
Date ISRCTN assigned 03/02/2003
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© ISRCTN


BioMed Central